Minimal Residual Disease Testing: Global Markets and Technologies

Minimal Residual Disease Testing: Global Markets and Technologies

Report Scope:

The report’s scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies’ mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

Report Includes:

44 data tables and 45 additional tables

An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing

Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028

Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region

In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market

Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations

Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse

Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry

A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities

Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration

Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics

Companies Mentioned

ADAPTIVE BIOTECHNOLOGIES CORP.
AMGEN INC.
ASTRAZENECA PLC
BIO-RAD LABORATORIES INC.
CERGENTIS B.V.
EXACT SCIENCES CORP.
GUARDANT HEALTH INC.
ILLUMINA INC. (GRAIL LLC)
INVITAE
INVIVOSCRIBE INC.
NATERA INC.
NEOGENOMICS INC.
QIAGEN
SYSMEX CORP.